Novel Biomarkers in Alzheimer's Disease
Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a criti...
I tiakina i:
| Hōputu: | Online |
|---|---|
| Reo: | Ingarihi |
| I whakaputaina: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Ngā marau: | |
| Urunga tuihono: | ONIX_20210501_9783039439034_107 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
| _version_ | 1869527764744273920 |
|---|---|
| collection | Directory of Open Access Books |
| description | Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD. |
| format | Online |
| id | doab-20.500.12854ir-68362 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-683622024-03-31T13:09:55Z Novel Biomarkers in Alzheimer's Disease Villa, Chiara flotillin Alzheimer’s disease biomarker exosomes beta-amyloid Tau aging biomarkers cytokines cognitive decline metabolomics neuroinflammation multivariate analysis physical performance person-tailored PET/CT (18F)FDG neuropsychological assessment APP mutations APOE alleles PSEN1 PSEN2 germline mutations late onset AD early onset AD familial AD genetics of AD mitochondrial spare respiratory capacity mitochondrial membrane potential glycolytic reserve semantic memory phonemic fluency episodic memory neuropsychology neuroimaging Alzheimer's disease mild cognitive impairment EEG TMS obesity diabetes inflammation Amyloid Beta mitochondrial dysfunction nutrition omega-3 fatty acids antioxidant carotenoids vitamin E cognition older adults ageing subjective cognitive decline clock genes Clock ApoE cardiovascular risk factors Alzheimer disease semantic priming amyloid beta cerebrospinal fluid amyloid beta peptide total tau phosphorylated tau diagnosis drug development clinical trials diagnostic research virus bacteria dementia blood behavioral and psychological symptoms of dementia (BPSD) Alzheimer’s disease (AD) neuropsychiatry inventory scale (NPI) endophenotypes CART analysis MTHFR APOE COMT genetic variants early diagnosis biofluids amyloid cascade hypothesis glucose metabolism adipose tissue dysfunction energetic metabolism lysosomes dysfunction Type-3-Diabetes neurodegeneration amyloid tau soluble TREM2 NfL Multiplex SiMoA diagnostics messenger RNA microRNA neurotropic microbes precision medicine prognostics synaptic biomarkers neurofilament light chain n/a thema EDItEUR::M Medicine and Nursing Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD. 2021-05-01T15:08:09Z 2021-05-01T15:08:09Z 2021 book ONIX_20210501_9783039439034_107 9783039439034 9783039439041 https://directory.doabooks.org/handle/20.500.12854/68362 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/3371 https://mdpi.com/books/pdfview/book/3371 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03943-904-1 10.3390/books978-3-03943-904-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039439034 9783039439041 442 Basel, Switzerland open access |
| spellingShingle | flotillin Alzheimer’s disease biomarker exosomes beta-amyloid Tau aging biomarkers cytokines cognitive decline metabolomics neuroinflammation multivariate analysis physical performance person-tailored PET/CT (18F)FDG neuropsychological assessment APP mutations APOE alleles PSEN1 PSEN2 germline mutations late onset AD early onset AD familial AD genetics of AD mitochondrial spare respiratory capacity mitochondrial membrane potential glycolytic reserve semantic memory phonemic fluency episodic memory neuropsychology neuroimaging Alzheimer's disease mild cognitive impairment EEG TMS obesity diabetes inflammation Amyloid Beta mitochondrial dysfunction nutrition omega-3 fatty acids antioxidant carotenoids vitamin E cognition older adults ageing subjective cognitive decline clock genes Clock ApoE cardiovascular risk factors Alzheimer disease semantic priming amyloid beta cerebrospinal fluid amyloid beta peptide total tau phosphorylated tau diagnosis drug development clinical trials diagnostic research virus bacteria dementia blood behavioral and psychological symptoms of dementia (BPSD) Alzheimer’s disease (AD) neuropsychiatry inventory scale (NPI) endophenotypes CART analysis MTHFR APOE COMT genetic variants early diagnosis biofluids amyloid cascade hypothesis glucose metabolism adipose tissue dysfunction energetic metabolism lysosomes dysfunction Type-3-Diabetes neurodegeneration amyloid tau soluble TREM2 NfL Multiplex SiMoA diagnostics messenger RNA microRNA neurotropic microbes precision medicine prognostics synaptic biomarkers neurofilament light chain n/a thema EDItEUR::M Medicine and Nursing Novel Biomarkers in Alzheimer's Disease |
| title | Novel Biomarkers in Alzheimer's Disease |
| title_full | Novel Biomarkers in Alzheimer's Disease |
| title_fullStr | Novel Biomarkers in Alzheimer's Disease |
| title_full_unstemmed | Novel Biomarkers in Alzheimer's Disease |
| title_short | Novel Biomarkers in Alzheimer's Disease |
| title_sort | novel biomarkers in alzheimer s disease |
| topic | flotillin Alzheimer’s disease biomarker exosomes beta-amyloid Tau aging biomarkers cytokines cognitive decline metabolomics neuroinflammation multivariate analysis physical performance person-tailored PET/CT (18F)FDG neuropsychological assessment APP mutations APOE alleles PSEN1 PSEN2 germline mutations late onset AD early onset AD familial AD genetics of AD mitochondrial spare respiratory capacity mitochondrial membrane potential glycolytic reserve semantic memory phonemic fluency episodic memory neuropsychology neuroimaging Alzheimer's disease mild cognitive impairment EEG TMS obesity diabetes inflammation Amyloid Beta mitochondrial dysfunction nutrition omega-3 fatty acids antioxidant carotenoids vitamin E cognition older adults ageing subjective cognitive decline clock genes Clock ApoE cardiovascular risk factors Alzheimer disease semantic priming amyloid beta cerebrospinal fluid amyloid beta peptide total tau phosphorylated tau diagnosis drug development clinical trials diagnostic research virus bacteria dementia blood behavioral and psychological symptoms of dementia (BPSD) Alzheimer’s disease (AD) neuropsychiatry inventory scale (NPI) endophenotypes CART analysis MTHFR APOE COMT genetic variants early diagnosis biofluids amyloid cascade hypothesis glucose metabolism adipose tissue dysfunction energetic metabolism lysosomes dysfunction Type-3-Diabetes neurodegeneration amyloid tau soluble TREM2 NfL Multiplex SiMoA diagnostics messenger RNA microRNA neurotropic microbes precision medicine prognostics synaptic biomarkers neurofilament light chain n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | flotillin Alzheimer’s disease biomarker exosomes beta-amyloid Tau aging biomarkers cytokines cognitive decline metabolomics neuroinflammation multivariate analysis physical performance person-tailored PET/CT (18F)FDG neuropsychological assessment APP mutations APOE alleles PSEN1 PSEN2 germline mutations late onset AD early onset AD familial AD genetics of AD mitochondrial spare respiratory capacity mitochondrial membrane potential glycolytic reserve semantic memory phonemic fluency episodic memory neuropsychology neuroimaging Alzheimer's disease mild cognitive impairment EEG TMS obesity diabetes inflammation Amyloid Beta mitochondrial dysfunction nutrition omega-3 fatty acids antioxidant carotenoids vitamin E cognition older adults ageing subjective cognitive decline clock genes Clock ApoE cardiovascular risk factors Alzheimer disease semantic priming amyloid beta cerebrospinal fluid amyloid beta peptide total tau phosphorylated tau diagnosis drug development clinical trials diagnostic research virus bacteria dementia blood behavioral and psychological symptoms of dementia (BPSD) Alzheimer’s disease (AD) neuropsychiatry inventory scale (NPI) endophenotypes CART analysis MTHFR APOE COMT genetic variants early diagnosis biofluids amyloid cascade hypothesis glucose metabolism adipose tissue dysfunction energetic metabolism lysosomes dysfunction Type-3-Diabetes neurodegeneration amyloid tau soluble TREM2 NfL Multiplex SiMoA diagnostics messenger RNA microRNA neurotropic microbes precision medicine prognostics synaptic biomarkers neurofilament light chain n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20210501_9783039439034_107 |